Perrigo (NYSE:PRGO) has been given a $105.00 price target by analysts at Canaccord Genuity in a note issued to investors on Monday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 30.45% from the stock’s previous close.
PRGO has been the subject of a number of other reports. Cantor Fitzgerald set a $107.00 target price on shares of Perrigo and gave the company a “buy” rating in a research report on Friday, January 5th. Oppenheimer reiterated a “buy” rating and issued a $98.00 target price on shares of Perrigo in a research report on Tuesday, February 27th. Berenberg Bank initiated coverage on shares of Perrigo in a research report on Thursday, February 1st. They issued a “buy” rating and a $117.00 target price for the company. Finally, JPMorgan Chase reiterated a “neutral” rating and issued a $83.00 target price (up from $82.00) on shares of Perrigo in a research report on Monday, March 5th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $93.44.
PRGO opened at $80.49 on Monday. The company has a current ratio of 1.96, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a market cap of $11,483.57, a price-to-earnings ratio of 16.33, a P/E/G ratio of 2.02 and a beta of 0.76. Perrigo has a 52-week low of $63.68 and a 52-week high of $95.93.
Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, March 1st. The company reported $1.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.03. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The company’s revenue was down 3.6% compared to the same quarter last year. During the same period last year, the firm posted $1.24 earnings per share. research analysts anticipate that Perrigo will post 5.23 earnings per share for the current fiscal year.
In other news, CEO Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The stock was purchased at an average cost of $81.85 per share, for a total transaction of $613,875.00. Following the completion of the transaction, the chief executive officer now owns 4,900 shares in the company, valued at $401,065. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC increased its position in Perrigo by 25.4% during the fourth quarter. TIAA CREF Investment Management LLC now owns 409,330 shares of the company’s stock worth $35,677,000 after purchasing an additional 82,848 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in Perrigo by 56.6% during the fourth quarter. State of Alaska Department of Revenue now owns 22,063 shares of the company’s stock worth $1,922,000 after buying an additional 7,970 shares during the period. Financial Sense Advisors Inc. boosted its stake in Perrigo by 4.7% during the fourth quarter. Financial Sense Advisors Inc. now owns 35,477 shares of the company’s stock worth $3,092,000 after buying an additional 1,600 shares during the period. OppenheimerFunds Inc. boosted its stake in Perrigo by 14.6% during the fourth quarter. OppenheimerFunds Inc. now owns 8,900 shares of the company’s stock worth $776,000 after buying an additional 1,131 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Perrigo by 38.0% during the third quarter. Russell Investments Group Ltd. now owns 18,889 shares of the company’s stock worth $1,599,000 after buying an additional 5,203 shares during the period. Hedge funds and other institutional investors own 79.09% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Perrigo (PRGO) PT Set at $105.00 by Canaccord Genuity” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/25/perrigo-prgo-pt-set-at-105-00-by-canaccord-genuity-2.html.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.